Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 2/20 | 0.46 |
| ▸ | TACR2 | P21452 | 5/20 | 0.45 |
| ▸ | REN | P00797 | 8/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
| ▸ | YAP1 | P46937 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5833515 | 0.88 | CACNA1B (0.46) | PSMB5RENYAP1 | |
| SCHEMBL5833622 | 0.88 | CTSS (0.49) | TACR2CTSSITGB3ITGA2BYAP1 | |
| SCHEMBL5833276 | 0.88 | TACR2 (0.44) | PSMB5TACR2RENCTSSKLKB1 | |
| SCHEMBL5833266 | 0.86 | TACR2 (0.47) | TACR2CTSSKLKB1ITGB3ITGA2B | |
| SCHEMBL5832747 | 0.85 | PSMB5 (0.42) | PSMB5RENKLKB1YAP1 | |
| SCHEMBL5832898 | 0.84 | MME (0.46) | PSMB5RENKLKB1YAP1 | |
| SCHEMBL5832902 | 0.84 | MME (0.46) | PSMB5RENKLKB1YAP1 | |
| SCHEMBL7337619 | 0.80 | CACNA1B (0.57) | PSMB5TACR2CTSS | |
| SCHEMBL7340969 | 0.80 | CACNA1B (0.57) | PSMB5TACR2CTSS | |
| SCHEMBL7398380 | 0.79 | CTSS (0.53) | PSMB5TACR2CTSSITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030060419-A1 | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | HU LAIN-YEN (US) | 2003-03-27 | — | — | US | claimed |
| US-6989448-B2 | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | HU LAIN-YEN | 2006-01-24 | — | — | US | disclosed |
| US-20030060419-A1 | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | HU LAIN-YEN (US) | 2003-03-27 | — | — | US | disclosed |
| US-6469038-B1 | CALCIUM CHANNEL BLOCKERS THAT CAN BLOCK N-TYPE CALCIUM CHANNELS AND CAN BE USED TO TREAT STROKE, PAIN, CEREBRAL ISCHEMIA, HEAD TRAUMA, ASTHMA, AMYOTROPIC LATERAL SCLEROSIS, AND EPILEPSY | WARNER-LAMBERT COMPANY | 2002-10-22 | — | — | US | disclosed |
| US-6166052-A | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | WARNER-LAMBERT COMPANY (US) | 2000-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060419-A1 | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | CACNA1C, CACNA1I, CACNA1S | PSMB5 430/4885TACR2 769/4885REN 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.